Overview

Assessment of V0018 1.5 mg Effect on Craving

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the reduction of craving after administration of V0018 1.5 mg compared to placebo in healthy moderately dependent smokers.

Phase:

Phase 2

Details

Lead Sponsor:

Pierre Fabre Medicament

Treatments:

Nicotine